PE20201494A1 - Anticuerpo anti-pacap - Google Patents
Anticuerpo anti-pacapInfo
- Publication number
- PE20201494A1 PE20201494A1 PE2020000375A PE2020000375A PE20201494A1 PE 20201494 A1 PE20201494 A1 PE 20201494A1 PE 2020000375 A PE2020000375 A PE 2020000375A PE 2020000375 A PE2020000375 A PE 2020000375A PE 20201494 A1 PE20201494 A1 PE 20201494A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- antibody
- variable region
- heavy chain
- light chain
- Prior art date
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 108060000200 adenylate cyclase Proteins 0.000 abstract 1
- 102000030621 adenylate cyclase Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 230000001817 pituitary effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a un anticuerpo que se une al peptido activador de la adenilato ciclasa de la pituitaria humana (PACAP), el cual comprende una region variable de cadena pesada (HCVR) es la SEQ ID NO.9 que comprende regiones determinantes de la complementariedad HCDR1 cuya secuencia de aminoacidos es la SEQ ID NO.3, HCDR2 es la SEQ ID NO.4 y HCDR3 es la SEQ ID NO.5; y comprende una region variable de cadena ligera (LCVR) es la SEQ ID NO. 10 que comprende LCDR1 es la SEQ ID NO.6, LCDR2 es la SEQ ID NO.7 y LCDR3 es la SEQ ID NO.8; asi como una cadena pesada (HC) que comprende la SEQ ID NO.1 y una cadena ligera (LC) que comprende la SEQ ID NO.2. Dicho anticuerpo es util en el tratamiento del dolor incluyendo cefalea y/o migrana.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762565278P | 2017-09-29 | 2017-09-29 | |
| PCT/US2018/051898 WO2019067293A1 (en) | 2017-09-29 | 2018-09-20 | ANTI-PACAP ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20201494A1 true PE20201494A1 (es) | 2020-12-29 |
Family
ID=63794713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000375A PE20201494A1 (es) | 2017-09-29 | 2018-09-20 | Anticuerpo anti-pacap |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10519225B2 (es) |
| EP (1) | EP3688035A1 (es) |
| JP (2) | JP6952888B2 (es) |
| KR (1) | KR102453573B1 (es) |
| CN (1) | CN111164105B (es) |
| AR (1) | AR113022A1 (es) |
| AU (1) | AU2018341959B2 (es) |
| BR (1) | BR112020003628A2 (es) |
| CA (1) | CA3077304C (es) |
| CL (1) | CL2020000705A1 (es) |
| CO (1) | CO2020002170A2 (es) |
| CR (1) | CR20200127A (es) |
| DO (1) | DOP2020000060A (es) |
| EA (1) | EA202090563A1 (es) |
| EC (1) | ECSP20020293A (es) |
| IL (1) | IL273529A (es) |
| JO (1) | JOP20200069A1 (es) |
| MA (1) | MA50654A (es) |
| MX (1) | MX2020003563A (es) |
| MY (1) | MY199876A (es) |
| NZ (1) | NZ762312A (es) |
| PE (1) | PE20201494A1 (es) |
| PH (1) | PH12020550340A1 (es) |
| SG (1) | SG11202002572YA (es) |
| TW (1) | TWI701260B (es) |
| WO (1) | WO2019067293A1 (es) |
| ZA (1) | ZA202001058B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017013113A (es) | 2015-04-16 | 2018-07-06 | Alder Biopharmaceuticals Inc | Anticuerpos anti-pacap y sus usos. |
| CA3020839A1 (en) | 2016-04-15 | 2017-10-19 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
| CA3154522A1 (en) | 2019-10-15 | 2021-04-22 | Christopher Carl Frye | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| CA3227549A1 (en) | 2021-07-29 | 2023-02-02 | Cephalon Llc | Compositions and methods for anti-pacap antibodies |
| WO2023051786A1 (zh) * | 2021-09-30 | 2023-04-06 | 江苏恒瑞医药股份有限公司 | 特异性结合cgrp和pacap的抗原结合分子及其医药用途 |
| KR102839881B1 (ko) * | 2021-11-19 | 2025-07-31 | 대한민국 | 방송통신기자재 성능 측정 시스템 및 그 방법 |
| WO2024218541A1 (en) * | 2023-04-20 | 2024-10-24 | Mark Hasleton | Treatment of migraine |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE210680T1 (de) * | 1990-03-17 | 2001-12-15 | Takeda Chemical Industries Ltd | Antikörper gegen hypophysäre adenylatzyklase aktivierende peptid-pacap, hybridome und bestimmung von pacap |
| US6037321A (en) | 1995-05-03 | 2000-03-14 | Biostar Inc. | Fusion proteins comprising vasoactive intestinal peptide or PACAP |
| FR2826747B1 (fr) | 2001-07-02 | 2005-02-25 | Gemplus Card Int | Procede et dispositif de traitement de donnees pour la personnalisation d'une application sur un dispositif communicant portatif, par exemple une carte a puce |
| US7615219B2 (en) | 2003-01-16 | 2009-11-10 | Life Sciences Research Partners Vzw | Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia |
| WO2012106407A2 (en) | 2011-02-01 | 2012-08-09 | The University Of Vermont And State Agricultural College | Diagnostic and therapeutic methods and products related to anxiety disorders |
| JP6064861B2 (ja) | 2013-03-05 | 2017-01-25 | 株式会社デンソー | 熱電変換装置の製造方法 |
| PE20151923A1 (es) * | 2013-03-15 | 2016-01-14 | Amgen Inc | Anticuerpos humanos pac1 |
| EP3035950A4 (en) | 2013-08-14 | 2017-05-03 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases |
| MX2017013113A (es) | 2015-04-16 | 2018-07-06 | Alder Biopharmaceuticals Inc | Anticuerpos anti-pacap y sus usos. |
| WO2017106578A1 (en) * | 2015-12-15 | 2017-06-22 | Amgen Inc. | Pacap antibodies and uses thereof |
| WO2017142961A1 (en) | 2016-02-16 | 2017-08-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Treatment of traumatic brain injury or stroke |
-
2018
- 2018-09-13 AR ARP180102618A patent/AR113022A1/es not_active Application Discontinuation
- 2018-09-14 TW TW107132467A patent/TWI701260B/zh active
- 2018-09-20 NZ NZ762312A patent/NZ762312A/en not_active IP Right Cessation
- 2018-09-20 CN CN201880063106.2A patent/CN111164105B/zh active Active
- 2018-09-20 EA EA202090563A patent/EA202090563A1/ru unknown
- 2018-09-20 WO PCT/US2018/051898 patent/WO2019067293A1/en not_active Ceased
- 2018-09-20 PH PH1/2020/550340A patent/PH12020550340A1/en unknown
- 2018-09-20 US US16/136,490 patent/US10519225B2/en active Active
- 2018-09-20 JP JP2020517489A patent/JP6952888B2/ja active Active
- 2018-09-20 PE PE2020000375A patent/PE20201494A1/es unknown
- 2018-09-20 KR KR1020207008789A patent/KR102453573B1/ko active Active
- 2018-09-20 CR CR20200127A patent/CR20200127A/es unknown
- 2018-09-20 MY MYPI2020001596A patent/MY199876A/en unknown
- 2018-09-20 AU AU2018341959A patent/AU2018341959B2/en active Active
- 2018-09-20 MA MA050654A patent/MA50654A/fr unknown
- 2018-09-20 BR BR112020003628-5A patent/BR112020003628A2/pt not_active Application Discontinuation
- 2018-09-20 SG SG11202002572YA patent/SG11202002572YA/en unknown
- 2018-09-20 CA CA3077304A patent/CA3077304C/en active Active
- 2018-09-20 JO JOP/2020/0069A patent/JOP20200069A1/ar unknown
- 2018-09-20 EP EP18783282.9A patent/EP3688035A1/en active Pending
- 2018-09-20 MX MX2020003563A patent/MX2020003563A/es unknown
-
2019
- 2019-11-22 US US16/692,236 patent/US10954292B2/en active Active
-
2020
- 2020-02-19 ZA ZA2020/01058A patent/ZA202001058B/en unknown
- 2020-02-27 CO CONC2020/0002170A patent/CO2020002170A2/es unknown
- 2020-03-16 DO DO2020000060A patent/DOP2020000060A/es unknown
- 2020-03-18 CL CL2020000705A patent/CL2020000705A1/es unknown
- 2020-03-23 IL IL273529A patent/IL273529A/en unknown
- 2020-03-26 EC ECSENADI202020293A patent/ECSP20020293A/es unknown
-
2021
- 2021-02-15 US US17/175,870 patent/US20210171616A1/en not_active Abandoned
- 2021-09-28 JP JP2021157701A patent/JP7221352B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20201494A1 (es) | Anticuerpo anti-pacap | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20191045A1 (es) | Anticuerpos anti-il-33 y usos de los mismos | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
| PE20170916A1 (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6 | |
| PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
| MX389805B (es) | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. | |
| PE20091351A1 (es) | Anticuerpos humanizados especificos para el factor von willebrand |